<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03411967</url>
  </required_header>
  <id_info>
    <org_study_id>APTN-L201712</org_study_id>
    <nct_id>NCT03411967</nct_id>
  </id_info>
  <brief_title>Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC</brief_title>
  <official_title>Clinical Study of Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC After Failure of Platinum-based Double-drug Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zigong No.1 Peoples Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zigong No.1 Peoples Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to explore a new treatment strategy for patients with failed NSCLC
      platinum-containing double-drug therapy, this study was to investigate the clinical efficacy
      of apatinib in combination with docetaxel for patients with advanced NSCLC after failure of
      platinum-based regime
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>6 month</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>12 month</time_frame>
    <description>Progress-Free Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib combine with docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.</description>
    <arm_group_label>apatinib combine with docetaxel</arm_group_label>
    <other_name>Aitan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment</description>
    <arm_group_label>apatinib combine with docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ECOG 0-2;

          2. Expected survival of not less than 12 weeks;

          3. The first line of platinum-containing chemotherapy, pathologically confirmed IIIB, IV
             non-small cell lung cancer, with measurable lesions (according to the RECIST 1.1
             standard, CT lesion tumor diameter ≥ 10mm, lymph node lesion CT scan diameter ≥ 15mm,
             measurable lesions have not received radiotherapy, local treatment such as freezing)

          4. The main organs function properly

          5. Women of childbearing age must have had reliable contraception or have had a pregnancy
             test (serum or urine) within 7 days prior to enrollment with a negative result and are
             willing to take appropriate measures 8 weeks after and during the last administration
             of the test drug contraception. In the case of males, consent is to be given to
             contraception or surgical sterilization 8 weeks after and during the last
             administration of the test drug;

          6. Participants volunteered to join the study and signed informed consent form, with good
             compliance and follow-up.

        Exclusion Criteria:

          1. Imaging (CT or MRI) showed tumor lesions away from the large blood vessels ≤ 5mm, or
             the presence of invasive central local blood vessels of the central tumor; or showed
             the presence of significant lung empty or necrotic tumors;

          2. Uncontrolled hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite
             optimal drug therapy);

          3. Has the following cardiovascular disease: Myocardial ischemia or myocardial infarction
             with grade II or higher, poorly controlled arrhythmia (including QTc intercourse men ≥
             450ms, women ≥ 470ms); NYHA class III-IV cardiomyopathy, Or cardiac ultrasound
             examination prompted left ventricular ejection fraction (LVEF) &lt;50%;

          4. Hemoptysis (INR&gt; 1.5 or Prothrombin Time (PT)&gt; ULN + 4 seconds or APTT&gt; 1.5ULN) with
             bleeding tendency or undergoing thrombolytic or anticoagulant therapy;

          5. In the first 2 months before enrollment, there is obvious slightly blood, or daily
             hemoptysis volume of 2.5ml or more;

          6. Within 3 months prior to enrollment, significant clinically significant bleeding
             symptoms or definite bleeding tendencies such as gastrointestinal bleeding,
             hemorrhagic gastric ulcer, fecal occult blood ++ at baseline, and above, or
             vasculitis;

          7. Incidence of arterial / venous thrombosis within the first 12 months of enrollment
             such as cerebrovascular accident (including transient ischemic attack, cerebral
             hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;

          8. Known hereditary or acquired bleeding and thrombophilia (eg hemophilia, coagulopathy,
             thrombocytopenia, hypersplenism, etc);

          9. Factors that significantly affect the absorption of oral drugs, such as
             non-swallowing, chronic diarrhea and intestinal obstruction;

         10. Urine routine urinary protein ≥ ++, or confirmed 24-hour urinary protein content ≥
             2.0g;

         11. Previous or concurrent with other unhealed malignancies, except for those having had a
             cure for cutaneous basal cell carcinoma, carcinoma of the cervix, and superficial
             bladder cancer;

         12. Pregnant or lactating women; Reproductive patients who are unwilling or unable to take
             effective contraception;

         13. The investigators determine other situations that may affect clinical research and
             outcome decisions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>132100694 132100694, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zigong No.1 People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Yan, M.D.</last_name>
    <phone>868132100694</phone>
    <email>13210069400@163.com</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

